PulseAugur
EN
LIVE 00:42:18
中文(ZH) “北赛泓升”完成A+轮融资

北赛泓升 completes A+ funding round led by Oriental Fortune Capital

By PulseAugur Editorial · [1 sources] ·

Beisai Hongsheng has successfully completed its Series A+ funding round, with Oriental Fortune leading the investment. The company plans to utilize these funds to accelerate its preclinical and clinical research for its core development pipelines. This funding will also bolster its leading positions in induced pluripotent stem cell (iPSC) and tissue-specific small molecule technology platforms, aiming to explore therapeutic potential across a wider range of diseases. AI

IMPACT Funding will accelerate research and development in iPSC and small molecule platforms, potentially leading to new therapeutic applications.

RANK_REASON Company announces completion of a significant funding round led by a venture capital firm. [lever_c_demoted from significant: ic=1 ai=0.4]

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

北赛泓升 completes A+ funding round led by Oriental Fortune Capital

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Research
Company announces completion of a significant funding round led by a venture capital firm. [lever_c_demoted from significant: ic=1 ai=0.4]
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
funding, product
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Standard
On-topic for AI-industry coverage; kept in the public index.
Story freshness
143 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Beisai Hongsheng Completes A+ Round Financing

    36氪获悉，近日，“北赛泓升”宣布完成A+轮融资。本轮融资由东方富海领投，产业基金及川创投共同投资，老股东上实资本旗下上海生物医药基金持续加码。资金将主要用于加速推进公司多条核心研发管线的临床前及临床研究，并进一步夯实公司在诱导多能干细胞（iPSC）与组织特异性小分子两大技术平台上的领先优势，持续探索其在更广泛疾病领域的治疗潜力。

RELATED TOPICS